DUBLIN--(BUSINESS WIRE)--The "Global Bispecific Antibody Drug Conjugates Clinical Trials, Regulatory Approvals & Future Market Opportunity Outlook 2029" report has been added to ...

Bispecific antibody drug conjugates (BsADCs) are an innovative class of therapeutics that combine the dual-targeting capabilities of bispecific antibodies with the cytotoxic payloads ...

BioNTech (NASDAQ:BNTX) said it has agreed to buy bispecific antibody developer Biotheus for up to $950M, including $150M in potential milestone payments. Under the deal, BioNTech (BNTX ...

Collaboration initiates development of dual-payload bispecific antibody-drug conjugates (BsAD2Cs) Biocytogen’s RenLite® meets Acepodia’s AD2C for precision oncology solutions BEIJING ...

SHANGHAI, March 5, 2025 /PRNewswire/ -- SanyouBio announced today the official launch of 73 whole-series bispecific antibody reference products, covering globally approved and representative ...

BNT327, a bispecific antibody candidate under development by BioNTech (NASDAQ:BNTX) that is seen as critical to the biotech's future success, will compete favorably against rival Summit ...

US-based startup Bambusa Therapeutics has secured $90m in Series A financing to advance its pipeline of bispecific antibodies for immunological and inflammatory disorders into the clinic.

Veraxa Biotech has entered a joint discovery partnership with OmniAb tp develop a bispecific antibody drug conjugate (bsADC) programme aimed at solid tumours. The partnership unites OmniAb's ...

LBL-034 is an investigational GPRC5D-targeted CD3 bispecific antibody. The Food and Drug Administration (FDA) has granted Orphan Drug designation to LBL-034 for the treatment of multiple myeloma.

Talquetamab, a bispecific antibody against CD3 and GPRC5D, redirects T cells to mediate killing of GPRC5D-expressing myeloma cells. In a phase 1 study, we evaluated talquetamab administered ...